Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder

ClinicalTrials.gov ID: NCT03187769

Public ClinicalTrials.gov record NCT03187769. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults With Schizophrenia, Schizophreniform, or Bipolar I Disorder Who Are Early in Their Illness

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will evaluate the effect of ALKS 3831 compared to olanzapine on body weight in young adults with schizophrenia, schizophreniform, or bipolar I disorder who are early in their illness

Study identification

NCT ID
NCT03187769
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Alkermes, Inc.
Industry
Enrollment
426 participants

Conditions and interventions

Eligibility (public fields only)

Age range
16 Years to 40 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 8, 2017 (Actual)
Primary completion
Dec 1, 2021 (Actual)
Completion
Jan 3, 2022 (Actual)
Last update posted
Jan 19, 2023

2017 – 2022

United States locations

U.S. sites
25
U.S. states
11
U.S. cities
22
Facility City State ZIP Site status
Alkermes Investigational Site Little Rock Arkansas 72211 —
Alkermes Investigational Site Rogers Arkansas 72758 —
Alkermes Investigational Site Garden Grove California 92845 —
Alkermes Investigational Site San Diego California 92013 —
Alkermes Investigational Site Stanford California 94305 —
Alkermes Investigational Site Jacksonville Florida 32209 —
Alkermes Investigational Site North Miami Florida 33161 —
Alkermes Investigational Site Atlanta Georgia 30303 —
Alkermes Investigational Site Atlanta Georgia 30331 —
Alkermes Investigational Site Augusta Georgia 30912 —
Alkermes Investigational Site Chicago Illinois 60611 —
Alkermes Investigational Site Winfield Illinois 60190 —
Alkermes Investigational Site Kalamazoo Michigan 49001 —
Alkermes Investigational Site Kansas City Missouri 64108 —
Alkermes Investigational Site St Louis Missouri 63110 —
Alkermes Investigational Site St Louis Missouri 63118 —
Alkermes Investigational Site St Louis Missouri 63128 —
Alkermes Investigational Site Las Vegas Nevada 89102 —
Alkermes Investigational Site Cincinnati Ohio 45219 —
Alkermes Investigational Site Eugene Oregon 97401 —
Alkermes Investigational Site DeSoto Texas 75115 —
Alkermes Investigational Site Fort Worth Texas 76104 —
Alkermes Investigational Site Houston Texas 77030 —
Alkermes Investigational Site Richardson Texas 75080 —
Alkermes Investigational Site San Antonio Texas 78201 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03187769, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 19, 2023 · Synced Oct 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT03187769 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →